Retrospective Cohort Study
Copyright ©The Author(s) 2015.
World J Orthop. Jun 18, 2015; 6(5): 439-445
Published online Jun 18, 2015. doi: 10.5312/wjo.v6.i5.439
Table 1 Cohort characteristics by treatment group n (%)
VariableNone (n = 84)Responder (n = 20)Non-responder (n = 8)
Sex
Male22 (26)9 (45)5 (62)
Female62 (74)11 (55)3 (38)
Age85 (± 7)82 (± 9)88 (± 4)
ASA class
1-227 (32)1 (5)0 (0)
3-457 (68)19 (95)8 (100)
Fracture type
Femoral neck23 (27)8 (40)0 (0)
Per/subthrochanteric46 (55)8 (40)7 (88)
Periprostethic15 (18)4 (20)1 (12)
Surgery
Hemi/total arthroplasty23 (27)8 (40)0 (0)
Sliding hips screw or intramedullary nail46 (55)8 (40)7 (88)
Locking plate osteosynthesis6 (7)1 (5)1 (12)
Revision of implants9 (11)3 (15)0 (0)
Table 2 Bleeding, erythrocyte transfusions and adverse events up to 3 mo follow-up
VariableControl (n = 84)Responder (n = 20)Non-responder (n = 8)P-value
Peroperative bleedning (mean ± SD)350 (0-1800)300 (50-1500)150 (50-550)0.82
Any erythrocyte transfusion, n (%)54 (64)13 (65)6 (75)
Number of transfusions, median (range)2 (0-10)1 (0-6)2 (0-6)1.02
Time to surgery (h), mean ± SD21 (± 12)45 (± 26)28 (± 33)0.0032
Adverse events
Any AE, n (%)31 (37)9 (45)5 (62)1.03
Type of AE, n1
Deceased, n1423
Hip related620
Cardiovascular813
Infection1494
Other2463
Table 3 Anaesthesia and transfusions n (%)
VariableControl (n = 84)Responder (n = 20)Non-responder (n = 8)P-value
Anaesthesia
Spinal82 (98)5 (25)7 (88)1
General2 (2)15 (75)1 (12)
Tranexamic acid
No9 (11)3 (15)0 (0)
Yes75 (89)17 (85)8 (100)0.003
Plasma transfusion transfusion
No83 (99)15 (75)7 (88)
Yes1 (1)5 (25)1 (12)0.003
Thrombocyte transfusion
No84 (100)9 (45)7 (88)
Yes0 (0)11 (55)1 (12)0.003